← Company directoryNASDAQ · SEC EDGAR
Regeneron Pharmaceuticals, Inc.
REGNA primary-source company identity page built for fast discovery, filing verification and consistent financial research.
SHARE PRICE · INDICATIVE——
A recent price could not be verified. Check the exchange before trading.
ANALYSIS ROUTE
Four checks before any decision
Business model
Understand how the company earns and where demand originates.
Revenue and margin
Compare equivalent periods; separate growth from profitability.
Debt and cash flow
Test balance-sheet resilience and cash conversion.
Valuation and risk
Use sector peers, scenarios and explicit risk limits.
Dates connected to this company
Confirmed events from the FinRatex financial calendar, linked to their named sources.
Regeneron third-quarter results
Regeneron will report its third-quarter 2026 financial and operating results before U.S. markets open on October 30. The company did not disclose an exact release time; its results call begins that day at 8:30 AM EDT / 3:30 PM Istanbul.
Regeneron ↗Regeneron third-quarter earnings call
Regeneron management will discuss the third-quarter results due before the October 30 U.S. market open during its conference call and webcast at 8:30 AM EDT / 3:30 PM Istanbul.
Regeneron ↗More NASDAQ records
Alphabetically adjacent directory records for faster navigation; this is not a peer or valuation classification.
REFRResearch Frontiers IncorporatedNASDAQ · SEC→REGRegency Centers CorporationNASDAQ · SEC→REGCORegency Centers Corporation - 5.875% Series B Cumulative Redeemable Preferred StockNASDAQ · SEC→REGCPRegency Centers Corporation - 6.25% Series A Cumulative Redeemable Preferred StockNASDAQ · SEC→REKRRekor Systems, Inc.NASDAQ · SEC→RELLRichardson Electronics, Ltd.NASDAQ · SEC→RELYRemitly Global, Inc.NASDAQ · SEC→RENTRent the Runway, Inc.NASDAQ · SEC→
DATA STATUS
Open official filings ↗Checking SEC financial statements
A dash means standardized data is unavailable. Always check the filing period, currency and accounting scope.